Literature DB >> 14511768

Perillyl alcohol and perillaldehyde induced cell cycle arrest and cell death in BroTo and A549 cells cultured in vitro.

J Abiodun Elegbede1, Richard Flores, Robert C Wang.   

Abstract

The role of the monoterpenes, especially limonene and perillyl alcohol, in the treatment of certain cancers is currently being evaluated in clinical trials. In this study, the effects of perillyl alcohol (POH) and its analog, perillaldehyde (PALD), on human carcinoma cell lines (BroTo and A549) cultured in vitro were investigated using proliferation assays (MTT and colony formation) and DNA content analysis by flow cytometry. POH and PALD elicited dose- and time-dependent inhibition of proliferation in both cell lines. Concentrations of POH and PALD that inhibited cell proliferation by 50% (IC50) in 24 hr were 1 and 3 mM, respectively. DNA content analysis revealed that 1 mM of either POH or PALD caused cell cycle arrest in the G1 phase in both cell lines while POH alone caused increased hypodiploid and annexin V-positive populations in both BroTo and A549 cells. POH induced apoptosis and was more effective than PALD at inhibiting the proliferation of BroTo and A549 cells cultured in vitro.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14511768     DOI: 10.1016/s0024-3205(03)00701-x

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  14 in total

Review 1.  Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy.

Authors:  Thomas C Chen; Clovis O Da Fonseca; Axel H Schönthal
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

Review 2.  Isoprenoids: remarkable diversity of form and function.

Authors:  Sarah A Holstein; Raymond J Hohl
Journal:  Lipids       Date:  2004-04       Impact factor: 1.880

3.  Perillyl alcohol and methyl jasmonate sensitize cancer cells to cisplatin.

Authors:  Laxmi Yeruva; Casey Hall; John Abiodun Elegbede; Stephen W Carper
Journal:  Anticancer Drugs       Date:  2010-01       Impact factor: 2.248

Review 4.  Cancer prevention with promising natural products: mechanisms of action and molecular targets.

Authors:  Poyil Pratheeshkumar; Chakkenchath Sreekala; Zhuo Zhang; Amit Budhraja; Songze Ding; Young-Ok Son; Xin Wang; Andrew Hitron; Kim Hyun-Jung; Lei Wang; Jeong-Chae Lee; Xianglin Shi
Journal:  Anticancer Agents Med Chem       Date:  2012-12       Impact factor: 2.505

Review 5.  Molecular mechanisms involved in farnesol-induced apoptosis.

Authors:  Joung Hyuck Joo; Anton M Jetten
Journal:  Cancer Lett       Date:  2009-06-10       Impact factor: 8.679

6.  Perillaldehyde Inhibition of cGAS Reduces dsDNA-Induced Interferon Response.

Authors:  Lei Chu; Chenhui Li; Yongxing Li; Qiuya Yu; Huansha Yu; Chunhui Li; Wei Meng; Juanjuan Zhu; Quanyi Wang; Chen Wang; Shufang Cui
Journal:  Front Immunol       Date:  2021-04-22       Impact factor: 7.561

7.  Tumour-specific HMG-CoAR is an independent predictor of recurrence free survival in epithelial ovarian cancer.

Authors:  Donal J Brennan; Jenny Brändstedt; Elton Rexhepaj; Michael Foley; Fredrik Pontén; Mathias Uhlén; William M Gallagher; Darran P O'Connor; Colm O'Herlihy; Karin Jirstrom
Journal:  BMC Cancer       Date:  2010-04-01       Impact factor: 4.430

Review 8.  A review on bioactivities of perilla: progress in research on the functions of perilla as medicine and food.

Authors:  Miho Igarashi; Yoshifumi Miyazaki
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-11       Impact factor: 2.629

9.  Synthesis and Antiproliferative Activity of New Cyclodiprenyl Phenols against Select Cancer Cell Lines.

Authors:  Bastián Said; Iván Montenegro; Manuel Valenzuela; Yusser Olguín; Nelson Caro; Enrique Werner; Patricio Godoy; Joan Villena; Alejandro Madrid
Journal:  Molecules       Date:  2018-09-12       Impact factor: 4.411

10.  Perillaldehyde Inhibits AHR Signaling and Activates NRF2 Antioxidant Pathway in Human Keratinocytes.

Authors:  Yoko Fuyuno; Hiroshi Uchi; Mao Yasumatsu; Saori Morino-Koga; Yuka Tanaka; Chikage Mitoma; Masutaka Furue
Journal:  Oxid Med Cell Longev       Date:  2018-02-14       Impact factor: 6.543

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.